PE84899A1 - Formulaciones farmaceuticas que contienen voriconazol - Google Patents

Formulaciones farmaceuticas que contienen voriconazol

Info

Publication number
PE84899A1
PE84899A1 PE1998000539A PE00053998A PE84899A1 PE 84899 A1 PE84899 A1 PE 84899A1 PE 1998000539 A PE1998000539 A PE 1998000539A PE 00053998 A PE00053998 A PE 00053998A PE 84899 A1 PE84899 A1 PE 84899A1
Authority
PE
Peru
Prior art keywords
voriconazole
pharmaceutical formulations
formulations containing
4so3h
containing voriconazole
Prior art date
Application number
PE1998000539A
Other languages
English (en)
Inventor
Valerie Denise Harding
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE84899(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE84899A1 publication Critical patent/PE84899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

CARACTERIZADA PORQUE COMPRENDE VORICONAZOL Y UN DERIVADO DE CICLODEXTRINA DE FORMULA (I), DONDE R1a-g, R2a-g Y R3a-g SON OH Y O(CH2)4SO3H; AL MENOS UNO DE R1a-g ES O(CH2)4SO3H; CADA O(CH2)4SO3H PUEDE ESTAR EN FORMA DE UNA SAL DE METAL ALCALINO. LA RELACION EN LA QUE ESTAN PRESENTES ES DE 1:1 HASTA 1:10; LA SOLUBILIDAD DEL VORICONAZOL PUEDE INCREMENTARSE AL SER ENCAPSULADO MOLECULARMENTE CON EL DERIVADO DE SULFOALQUILETER DE CICLODEXTRINA, ADICIONALMENTE LA FORMULACION PUEDE ESTAR LIOFILIZADA MEJORANDO SU ESTABILIDAD
PE1998000539A 1997-06-21 1998-06-19 Formulaciones farmaceuticas que contienen voriconazol PE84899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PE84899A1 true PE84899A1 (es) 1999-09-17

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000539A PE84899A1 (es) 1997-06-21 1998-06-19 Formulaciones farmaceuticas que contienen voriconazol

Country Status (48)

Country Link
US (1) US6632803B1 (es)
EP (1) EP1001813B8 (es)
JP (2) JP2000513029A (es)
KR (1) KR100372988B1 (es)
CN (1) CN1125653C (es)
AP (1) AP912A (es)
AR (1) AR015900A1 (es)
AT (1) ATE238812T1 (es)
AU (1) AU724799B2 (es)
BG (1) BG64584B1 (es)
BR (1) BRPI9809468B8 (es)
CA (1) CA2295035C (es)
CO (1) CO4940450A1 (es)
CZ (1) CZ289570B6 (es)
DE (1) DE69814091T2 (es)
DK (1) DK1001813T3 (es)
DZ (1) DZ2523A1 (es)
EA (1) EA001924B1 (es)
EG (1) EG23910A (es)
ES (1) ES2195355T3 (es)
GB (1) GB9713149D0 (es)
HK (1) HK1027966A1 (es)
HR (1) HRP980341B1 (es)
HU (1) HU228338B1 (es)
ID (1) ID22939A (es)
IL (1) IL132918A (es)
IS (1) IS2004B (es)
MA (1) MA26508A1 (es)
ME (1) ME00907B (es)
MY (1) MY118151A (es)
NO (1) NO313125B1 (es)
NZ (1) NZ501066A (es)
OA (1) OA11232A (es)
PA (1) PA8453201A1 (es)
PE (1) PE84899A1 (es)
PL (1) PL191295B1 (es)
PT (1) PT1001813E (es)
RS (1) RS49633B (es)
SA (1) SA98190159B1 (es)
SI (1) SI1001813T1 (es)
SK (1) SK282946B6 (es)
TN (1) TNSN98090A1 (es)
TR (1) TR199903191T2 (es)
TW (1) TW406023B (es)
UA (1) UA57083C2 (es)
UY (1) UY25055A1 (es)
WO (1) WO1998058677A1 (es)
ZA (1) ZA985364B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US7115587B2 (en) * 2002-08-20 2006-10-03 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
MXPA06006291A (es) * 2003-12-08 2006-08-23 Univ Arizona Composiciones anti-cancer sinergisticas.
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (en) * 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
US20110105448A1 (en) * 2008-06-06 2011-05-05 Glenmark Pharmaceuticals Limited Stable Topical Formulation Comprising Voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药***
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
WO2011020605A1 (en) 2009-08-19 2011-02-24 Ratiopharm Gmbh Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
BR112012033077B8 (pt) 2010-06-29 2023-04-25 Merck Sharp & Dohme Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
EP2409699B1 (en) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Stable compositions of voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
PL2720723T3 (pl) 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
EP2561863A1 (en) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmaceutical compositions comprising voriconazole
WO2013103924A2 (en) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
EP2662094B1 (en) 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
MX2014013714A (es) 2012-05-11 2015-08-10 Cipla Ltd Composicion farmaceutica.
CA2897330C (en) 2013-01-11 2021-01-26 Xellia Pharmaceuticals Aps Voriconazole inclusion complexes
US20140275122A1 (en) 2013-03-14 2014-09-18 Fresenius Kabi Usa, Llc Voriconazole Formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US11040958B2 (en) 2017-02-17 2021-06-22 Wuhan Ll Science And Technology Development Co., Ltd. Triazole antimicrobial derivative, pharmaceutical composition and use thereof
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
DE69814091T2 (de) 2004-01-22
BG64584B1 (bg) 2005-08-31
SA98190159B1 (ar) 2005-12-21
DZ2523A1 (fr) 2003-02-01
BRPI9809468B8 (pt) 2022-01-18
HK1027966A1 (en) 2001-02-02
MA26508A1 (fr) 2004-12-20
BR9809468B1 (pt) 2013-11-12
ATE238812T1 (de) 2003-05-15
CA2295035A1 (en) 1998-12-30
CA2295035C (en) 2005-04-19
CN1125653C (zh) 2003-10-29
AR015900A1 (es) 2001-05-30
EP1001813B1 (en) 2003-05-02
CO4940450A1 (es) 2000-07-24
NO995565L (no) 1999-11-30
PL337692A1 (en) 2000-08-28
US6632803B1 (en) 2003-10-14
ME00907B (me) 2007-08-03
EA199900937A1 (ru) 2000-08-28
CZ409699A3 (cs) 2000-02-16
RS49633B (sr) 2007-08-03
DK1001813T3 (da) 2003-07-28
SI1001813T1 (en) 2004-02-29
OA11232A (en) 2003-05-26
WO1998058677A1 (en) 1998-12-30
IS5248A (is) 1999-11-15
NO995565D0 (no) 1999-11-12
UA57083C2 (uk) 2003-06-16
SK159399A3 (en) 2000-06-12
TR199903191T2 (xx) 2000-09-21
CZ289570B6 (cs) 2002-02-13
PA8453201A1 (es) 2000-05-24
AP912A (en) 2001-12-08
GB9713149D0 (en) 1997-08-27
UY25055A1 (es) 2000-12-29
HU228338B1 (en) 2013-03-28
TNSN98090A1 (fr) 2005-03-15
BG103882A (en) 2000-07-31
NO313125B1 (no) 2002-08-19
ES2195355T3 (es) 2003-12-01
ZA985364B (en) 1999-12-20
KR20010014006A (ko) 2001-02-26
NZ501066A (en) 2001-01-26
EG23910A (en) 2007-12-30
HUP0003323A3 (en) 2002-01-28
SK282946B6 (sk) 2003-01-09
IL132918A (en) 2001-09-13
KR100372988B1 (ko) 2003-02-25
IL132918A0 (en) 2001-03-19
IS2004B (is) 2005-04-15
YU68199A (sh) 2002-06-19
JP2000513029A (ja) 2000-10-03
AU8110498A (en) 1999-01-04
JP2002332234A (ja) 2002-11-22
EP1001813A1 (en) 2000-05-24
HRP980341B1 (en) 2001-12-31
MY118151A (en) 2004-09-30
TW406023B (en) 2000-09-21
ID22939A (id) 1999-12-16
BR9809468A (pt) 2000-06-20
EA001924B1 (ru) 2001-10-22
AP9801268A0 (en) 1998-06-30
PT1001813E (pt) 2003-07-31
EP1001813B8 (en) 2014-02-12
JP5089004B2 (ja) 2012-12-05
PL191295B1 (pl) 2006-04-28
HRP980341A2 (en) 1999-02-28
AU724799B2 (en) 2000-09-28
HUP0003323A2 (hu) 2001-06-28
DE69814091D1 (de) 2003-06-05
CN1261287A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
ES2037620A1 (es) Procedimiento para la preparacion de una composicion para la limpieza de la piel, cuero cabelludo y cabello.
EA200300050A1 (ru) Гликопептидфосфонатные производные
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
ES2132676T3 (es) Composiciones de peroxigeno.
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
ES2181501T3 (es) Composicion cosmetica.
ES2175825T3 (es) Antitraspirante con dibencilidensorbitol.
ES2188763T3 (es) Factor del tipo relaxina y metodos y usos del mismo.
EA200300047A1 (ru) Прозрачное водное анестезирующее средство
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
DE602004015725D1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
ES2156375T3 (es) Composicion de champu acondicionador.
ATE473019T1 (de) Stabilisierung von wässerigen zusammensetzungen von 18f-markiertem 2-fluoro-2-deoxy-d-glukose mit ethanol
BR9904613A (pt) Utilização de uma goma de silicone, composição tópica e utilização de uma composição
BRPI0417366A (pt) composição detergente lìquida, método de limpeza de um substrato de tecido, e, uso de um antioxidante
CO5611210A2 (es) Composicion de jabon
ATE430571T1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol- verbindungen
ES2118105T3 (es) Composiciones de blanqueo activadas por acidos.
ES2082345T3 (es) Composicion del tipo de barra con cloruro de sodio y alcohol estearilico.
TR200002293T2 (tr) Farmasötik bileşimler.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term